OPKO Health (OPK) stock is in focus after OPKO Biologics shared preclinical results for its acromegaly candidate OPK8801001, highlighting strong, dose-dependent IGF-1 suppression and higher growth hormone receptor antagonism compared with existing therapy.

Following the ENDO 2026 update on OPK8801001, OPKO Health’s 30-day share price return of 27.27% and 90-day gain of 17.65% suggest building momentum. However, the 5-year total shareholder return, down 62.96%, underlines a tougher longer term journey.

If this kind of early stage biotech progress has your attention, it could be a good moment to broaden your watchlist with 39 healthcare AI stocks

So with OPKO Health stock up over the past month, a market value of about US$1.07b and analyst targets sitting higher than the last close, is this a genuine mispricing or is future growth already reflected in the price?

Most Popular Narrative: 58.8% Undervalued

On the most followed narrative, OPKO Health’s fair value of $3.40 sits well above the last close at $1.40, which naturally raises questions about what is embedded in those assumptions.

The sale of BioReference's oncology and related clinical testing assets to Labcorp is expected to sharpen OPKO Health's focus on its core testing business, drive significant cost savings, and support the Diagnostics segment's transition to cash flow positive and profitability in 2025, providing margin expansion and stabilizing earnings.

Curious what supports a valuation more than double the current OPKO Health share price? The narrative leans heavily on steadier revenue, higher margins and a steep shift in earnings power. The tension lies in how quickly that mix and profitability profile could change. The full breakdown sets out the specific revenue path, margin lift and future earnings multiple that back the $3.40 figure.

Result: Fair Value of $3.40 (UNDERVALUED)

However, OPKO Health’s story still carries clear execution risks, including ongoing losses of $212.9 million and reliance on less predictable revenue and partnership income to support the current narrative.

Another View on OPKO Health’s Valuation

The fair value narrative for OPKO Health centers on a future earnings recovery, but the current P/S of 1.8x tells a different story. It is higher than both the US Healthcare industry at 1.3x and the peer average at 1.5x, and well above the fair ratio of 0.5x. This points to meaningful valuation risk if expectations are not met.

For a closer look at what the current sales multiple implies for OPKO Health, take a moment to review the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mixed signals around OPKO Health, it makes sense to review the underlying data and pressure test the thesis yourself. Before forming a firm view, consider how the company’s 1 important warning sign could shape the balance between potential reward and downside risk for your portfolio.

Looking for more investment ideas beyond OPKO Health?

If OPKO Health has sharpened your focus, do not stop there. Use the Simply Wall Street Screener to uncover more targeted stock ideas built from the same data engine.

• Target income potential by reviewing 9 dividend fortresses that aim to combine higher yields with balance sheet resilience and consistent cash generation.
• Hunt for mispriced opportunities by scanning screener containing 20 high quality undiscovered gems that pair solid fundamentals with relatively low market attention.
• Prioritise capital preservation by filtering for 68 resilient stocks with low risk scores that score well on financial health and business stability metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.